Big Update from Actify Neurotherapies

A Note From Our New CEO, Kathy Kaluhiokalani


I am honored to join Actify Neurotherapies at an incredibly exciting time. It’s a privilege to be part of a fast growing healthcare company that delivers innovative, best-in-class treatment options that are making a meaningful difference in the lives of the many people dealing with major depressive disorders.  Actify Neurotherapies is positioned to expand treatment options and add new locations, while providing an exceptional patient experience.  I look forward to leading the company’s continued expansion, and enabling our team to execute on its mission to deliver evidenced-based, compassion-driven care.

The growth of Actify Neurotherapies comes at a vital time, as 16 million Americans every year suffer from depression, and millions more from PTSD, OCD, and other mental health disorders.  It is difficult to find care that is affordable, timely, and delivered in a patient centric environment.  Many of the current options are marginally effective and can leave sufferers committed to long-term treatment with burdensome and harmful side effects. It’s Actify’s mission to change the way healthcare approaches ambulatory mental health treatment and we are committed to bridging the gap between patients and providers, creating a continuity of effective care.

Together, we can Actify your care.

Regards,

Kathy Kaluhiokalani | Chief Executive Officer

Kathy Kaluhiokalani has been working in healthcare administration for over a decade. She brings a wealth of efficacy and experience to Actify Neurotherapies and is looking forward to enhancing our patients’ journeys every step of the way. Kathy is excited to be at the helm of Actify’s ship as we take the next step forward in ambulatory mental health care.